Effect of blocking Ras signaling pathway with K-Ras siRNA on apoptosis in esophageal squamous carcinoma cells  by Wang, Xinjie et al.
TOPIC
JTCM |www. journaltcm. com June15, 2013 |Volume 33 | Issue 3 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2013 June 15; 33(3): 361-366
info@journaltcm.com ISSN 0255-2922
© 2013 JTCM. All rights reserved.
EXPERIMENTAL STUDY
Effect of blocking Ras signaling pathway with K-Ras siRNA on apop-
tosis in esophageal squamous carcinoma cells
XinjieWang, Yuling Zheng, Qingxia Fan, Xudong Zhang
aa
Xinjie Wang, Department of Integrated Chinese and West-
ern Medicine, the First Affiliated Hospital, Zhengzhou Uni-
versity, Zhengzhou 450052, China
Yuling Zheng, Qingxia Fan, Xudong Zhang, Department
of Tumor, the First Affiliated Hospital, Zhengzhou University,
Zhengzhou 450052, China
Supported by the Natural Science Research Program of the
Education Department of Henan Province (No.
2011B320012)
Correspondence to: Prof. Yuling Zheng, Department of Tu-
mor, the First Affiliated Hospital, Zhengzhou University,
Zhengzhou 450052, China. zhengyl@zzu.edu.cn
Telephone: +86-13503817159
Accepted: September 14, 2012
Abstract
OBJECTIVE: To study the effect of RNAi silencing of
the K-Ras gene on Ras signal pathway activity in
EC9706 esophageal cancer cells.
METHODS: EC9706 cells were treated in the follow-
ing six groups: blank group (no transfection), nega-
tive control group (transfection no-carrier), trans-
fection group (transfected with pSilencer-siK-ras),
taxol chemotherapy group, taxol chemotherapy
plus no-carrier group, taxol chemotherapy plus
transfection group. Immunocytochemistry, Reverse
transcription-polymerase chain reaction and west-
ern blotting were used to analyze the expression of
MAPK1 (mitogen-activated protein kinases 1) and
cyclin D1 in response to siRNA (small interfering
RNA) transfection and taxol treatment.
RESULTS: K-Ras (K-Ras gene) siRNA transfection of
EC9706 esophageal squamous carcinoma cells de-
creased the expression of K-Ras, MAPK1 and cyclin
D1 at the mRNA and protein level. Reverse tran-
scription-polymerase chain reaction indicated that
the expression levels of MAPK1 and cyclin D1
mRNAs were significantly lower in the transfection
group than in the blank group (P<0.05). Western
blotting showed that 72 h after EC9706 cell trans-
fection, the expression levels of MAPK1 and cyclin
D1 proteins had decreased in all groups, and the ex-
pression levels in the transfection group were sig-
nificantly inhibited as compared with the blank
group. Apoptosis increased significantly in the
transfection group or after addition of taxol as com-
pared with the blank group and the no-carrier
group. The degree of apoptosis in the taxol plus
transfection group was more severe.
CONCLUSION: Apoptosis increased significantly in
EC9706 esophageal carcinoma cells after siRNA-me-
diated inhibition of Ras signaling, with the most ob-
vious increase observed in the transfection plus tax-
ol chemotherapy group. Ras knockdown therefore
increased cellular sensitivity to the chemotherapeu-
tic agent, taxol. Ras knockdown also down-regulat-
ed the expression of the downstream genes,
MAPK1 and cyclin D1, thus inhibiting the growth,
proliferation and metabolism of esophageal cancer
cells.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Carcinoma of the esophagus is a highly invasive, malig-
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nant tumor responsible for approximately 25% of all
malignant tumor deaths.1 Carcinoma of the esophagus
is clinically characterized by rapid advance, a tendency
for metastasis and recurrence, and poor prognosis.
Therefore, new techniques for treating carcinoma of
the esophagus, including the development of effective
drugs, are increasingly required.2 Ras gene mutations
are closely related to human tumors, particularly the
K-ras gene because of its high mutation rate. The Ras
(Ras gene) pathway is a highly conserved signal trans-
duction pathway that activates many other signaling
pathways to mediate differentiation, proliferation and
survival of cells, and proto-oncogene mediated transfor-
mation.3-5 Expression of the K-Ras gene in cancer tis-
sues in the esophagus and stomach is higher than in
the control tissues adjacent to the cancers,6-10 and ab-
normal expression of the Ras gene is closely related to
the development of esophageal cancer.11,12 In the pres-
ent study, the expression of MAPK1 (mitogen-activat-
ed protein kinases1) and cyclin D1 was investigated af-
ter Small interfering RNA (siRNA): silencing of the
K-Ras gene in the EC9706 esophageal cancer cell line
to investigate the value of targeting the K-ras gene for
cancer treatment.
MATERIALS ANDMETHODS
Reagents
Antibodies against K-Ras, MAPK and cyclin D1 were
purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA, USA). The restriction endonucleases, Bam-
HI and HindIII, were purchased from Bao Biological
Company (Tokyo, Japan).
Cell culture
The EC9706 esophageal cancer cell line, the plasmid,
pSilencer, and the bacterial strain, top10, were preserved
at the Key Laboratory of Tumor Pathology of Henan
Province (Zhengzhou, China). EC9706 cells were cul-
tured in a constant temperature, humidified incubator at
37℃ with 5% CO2. The cells were subcultured by di-
gesting with 0.25% trypsin solution. For experiments,
cells in the logarithmic growth phase were used.
Transfection
The cells were divided into six groups: blank group
(no-transfection control), no-carrier group (transfec-
tion no-carrier), transfection group (transfected with
pSilencer-siK-ras), taxol chemotherapy group, no-carri-
er + taxol chemotherapy group, and transfection+ taxol
chemotherapy group. The cells were inoculated in
6-well plates 1 day before transfection. On reaching
60%-80% confluence on the following day, the cells
were transfected with 5 mg of pSilencer siRNA plas-
mid and 10 mL of Lipofectamine 2000 in 240 mL of
Opti-MEM (Opti-MEM Reduced Serum Medium,
powder) serum-free medium. Taxol was then added to
the appropriate wells at a concentration of 0.1 µg/mL,
following which the cells were incubated at 37℃ for 48
or 72 h before replacing the medium. Total RNA was
extracted from the cells with Trizol, and the concentra-
tion and purity of the RNA were determined by ultra-
violet spectrophotometry.
Immunocytochemical analysis of Ras, MAPK1 and
cyclin D1 expression
Upon reaching confluence, the transfected cells were
fixed with 4% paraformaldehyde for 30min at 4℃, treat-
ed with 0.3% H2O2 at room temperature for 10 min to
block endogenous peroxidase activity, and then
blocked with 10% animal serum at room temperature
for 30 min. The cells were incubated with primary anti-
body at 4℃ overnight and then with secondary anti-
body at room temperature for 1 h. Bound antibodies
were detected by incubating the cells with SABC/DAB
at room temperature for 30-60 min before stopping
with tap-water, following which the cells were coun-
ter-stained with hematoxylin, dehydrated in a graded
series of alcohols and xylene for 20 min, and then
mounted in neutral resin.
Realtime Polymerase Chain Reaction (RT-PCR)
analysis of MAPK and cyclin D1 expression
Upstream and downstream primers for MAPK1 and cy-
clin D1 were designed using Primer Premier 5.0 soft-
ware (Primer company, Toronto, Canada). Five micro-
grams of RNA were reverse transcribed with Promega
MMLV (Moloney murine leukemia virus) reverse tran-
scriptase in a 20 µL reaction, and 0.5 µL of RT (Real-
time) product was amplified using SYBR® Premix Ex
TaqTM (TaKaRa).
Western blot analysis of MAPK and cyclin D1
expression
Seventy-two hours after transfection, the EC9706 cells
were lysed with RIPA buffer and the lysates were stored
at －80℃ prior to use. The lysates were separated on
10% SDS (Sodium dodecyl sulfate)-polyacrylamide
gels and transferred to nitrocellulose membranes (Milli-
pore company, MA, USA). After blocking with Blotto
blocking solution, the membranes were incubated with
primary and secondary antibodies.
Detection of apoptosis by TUNEL (terminal deoxynu-
cleotidyl transferase-mediated dUTP-biotin nick end
labeling assay) staining
Twenty-four hours after transfection, the EC9706 cells
were trypsinized, counted and resuspended at 6 × 104/
mL. The cells were inoculated in a 96-well plate (100μL per well) and 0.1 µg/mL taxol was added before fix-
ing the cells with 4% paraformaldehyde for 1 h at
room temperature. Then, 50 μL of TUNEL reaction
solution was added. After washing five times with 1×
PBS, the cells were observed under a fluorescence mi-
croscope and photographed.
Statistical analysis
Statistical analysis was performed using Student's t-test
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for the measurement data and the χ2 test for the enu-
meration data with SPSS10.0 software. (SPSS Cpmpa-
ny, Chicago, IL, USA), (P<0.05).
RESULTS
Immunocytochemical analysis of Ras, MAPK1 and
cyclin D1 expression
The expression of Ras protein in the transfection group
was significantly lower than in the blank group. After
addition of the chemotherapeutical agent, taxol, the ex-
pression of Ras protein decreased in the chemotherapy
group, the no-carrier + chemotherapy group and the
transfection+chemotherapy group, with the most obvi-
ous decrease observed in the transfection+chemothera-
py group (Figure 1).
The expression of MAPK protein in the transfection
group was slightly lower than in the blank group. After
addition of taxol, the expression of MAPK protein sig-
nificantly decreased, with the most obvious decrease
observed in the transfection + chemotherapy group
(Figure 2).
The expression of cyclin D1 decreased in the transfec-
tion group compared with the blank group. After addi-
tion of taxol, the expression of cyclin D1 in the three
groups significantly decreased, with the most obvious
decrease observed in the transfection + taxol group
(Figure 3).
FED
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Figure 1 Expression of K-Ras in the transferted cells
A: blank group; B: no-carrier group; C: transfection group; D: taxol chemotherapy group; E: no-carrier + taxol chemotherapy
group; F: transfection+taxol chemotherapy group. K-Ras: K-RAS gene; MAPK1: mitogen-activated protein kinases1.
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Figure 2 Expression of MAPK1 in the transfected cells
A: blank group; B: no-carrier group; C: transfection group; D: taxol chemotherapy group; E: no-carrier + taxol chemotherapy
group; F: transfection+taxol chemotherapy group. MAPK1: mitogen-activated protein kinases1.
A
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Effects of siRNA transfection on MAPK1 and cyclin
D1 expression by RT-PCR analysis
The expression of MAPK1 in the three groups
showed a tendency to decrease, with no significant
difference between the no-carrier group and the
blank group, and with a significant difference be-
tween the transfection group and the blank group (P<
0.05) (Table 1).
The expression of cyclin D1 protein in the three
groups showed a tendency to decrease, with no signifi-
cant difference between the no-carrier group and the
blank group, and with a significant difference between
the transfection group and the blank group (P<0.05)
(Tables 2, Figure 4).
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Figure 4 Expression of MAPK1 and cyclin D1 in the transfected
cells
A:MAPK1; B: Cyclin D1. MAPK1: mitogen-activated protein ki-
nases1; NC: no-carier; SiRas: small interference Ras.
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Figure 3 Expression of cyclin D1 in the transfected cells
A: blank group; B: no-carrier group; C: transfection group; D: taxol chemotherapy group; E: no-carrier + taxol chemotherapy
group; F: transfection+taxol chemotherapy group.
Actin
CyclinD1
ΔΔCt
Fold
Blank
(Control)
17.629 74
20.035 51
0
1
No-carier
17.7359
20.177 91
0.036 236
0.975 196
Transfec-
tion(SiRas)
17.763 04
20.746 19
0.577 373
0.670 183
P
value
<0.05
Table 2 Expression of cyclin D1 in the transfected cells
Note: SiRas: small interference Ras.
Actin
MAPK1
ΔΔCt
Fold
Blank
(Control)
17.629 74
18.4774
0
1
No-carrier
17.7359
18.6382
0.054 627
0.962 843
Transfec-
tion (SiRas)
17.763 04
19.051 86
0.441 153
0.441 153
P value
<0.05
Table 1 Expression of MAPK in the transfected cells
Notes: MAPK1: mitogen-activated protein kinases1; SiRas: small
interference Ras.
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Effects of siRNA transfection on MAPK1 and cyclin
D1 expression
Western blots show the significant inhibition of
MAPK1 and cyclin D1 expression in the siRas experi-
mental groups (Figure 5).
Figure 5 shows that 72 h after transfection of EC9706
cells, MAPK and cyclin D1 decreased in all groups,
and their expression was significantly inhibited in the
transfection group as compared with the blank group.
Cell nuclei were identified by DAPI (4',6-diamidi-
no-2-phenylindole), staining (blue fluorescence). In ad-
dition, the apoptotic cells emitted green fluorescence.
Therefore, apoptosis was determined according to the
ratio between blue and green fluorescence. Apoptosis
significantly increased after Ras siRNA transfection or
addition of taxol compared with the blank group and
the no-carrier group (Figure 6).
DISCUSSION
Mutation of the Ras gene is the most common onco-
gene abnormality, and it occurs in about 30% of hu-
man tumors. The Ras gene family includes the three
members, H-ras, K-ras and N-ras. Among them, muta-
tions in the K-ras gene, which is located on chromo-
some 12 with a length of about 45 000 base pairs, are
most common. Abnormal activation of the Ras gene
leads to the production of constitutively active p21ras
protein, which activates signaling molecules down-
stream of MAPK to induce unlimited proliferation and
tumor production.13 The high activity of Ras is often
accompanied by excessive phosphorylation and amplifi-
cation of ERK (Extracellular signal regulated kinase),
which promotes malignant transformation. Ras acti-
vates the MAPKKK (mitogen-activated protein kinase
kinase kinase)-MAPKK (mitogen-activated protein ki-
nase kinase)-MAPK signal transduction cascade14 to in-
duce cell proliferation via cyclin D1, the activity of
which is closely related to other cancer genes. In some
cell lines, cyclin D1 shows a weak cancer-inducing ac-
tion. Although it has no transforming action itself, it
can cooperate with the activated Ras gene to transform
rat fibroblasts.15 In the present study, siRNA interfer-
ence was used to silence the K-ras gene in the EC9706
esophageal cancer cell line and the expression of the
key signal proteins, MAPK1 and cyclin D1, down-
stream of Ras was investigated. The results indicated
that siRNA silencing of K-Ras in EC9706 cells led to
decreased expression of MAPK1 and cyclin D1.
RT-PCR analysis indicated that the expression of
MAPK1 and cyclin D1 was lower in the transfection
groups than in the blank group (P<0.05). Western blot
analysis showed that 72 h after transfection of EC9706
cells, the expression of MAPK1 and cyclin D1 proteins
decreased in all groups, with significant inhibition be-
ing observed in the transfection group as compared
Figure 5 Expression of MAPK1 and cyclin D1 proteins in the
cells transfected with K-Ras siRNA
MAPK1: mitogen-activated protein kinases1.
β-Tubulin
MAPK
Cyclin D1
kDa
55
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33
CELL NC siRas
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Figure 6 Morphological changes in the transfected cells (TUNEL assay)
A: blank group; B: no-carrier group; C: transfection group; D: taxol chemotherapy group; E: no-carrier + taxol chemotherapy
group; F: transfection+taxol chemotherapy group. TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end
labeling.
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with the blank group. Apoptosis significantly increased
in the transfection group or after addition of taxol, as
compared with the blank group and the no-carrier
group, and the degree of apoptosis was most severe in
the taxol plus transfection group.
The above results indicate that siRNA silencing of
K-Ras in vitro blocks the Ras signal transduction path-
way in the EC9706 esophageal carcinoma cell line and
significantly increases apoptosis. The degree of apopto-
sis was more severe in the transfection plus taxol che-
motherapy group. Ras knockdown therefore increased
cellular sensitivity to the chemotherapeutic agent, tax-
ol. Ras knockdown also down-regulated the expression
of the downstream genes, MAPK1 and cyclin D1, thus
inhibiting the growth, proliferation and metabolism of
esophageal cancer cells.
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